ArticleEuropean radiology2025
The efficacy of uterine artery embolization for postpartum hemorrhage with placenta accreta spectrum disorder: clinical outcomes in a cohord of 112 pregnant women.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Role of Interventional Radiology in the Diagnosis and Treatment of Gynecological Conditions.Tomography (Ann Arbor, Mich.) · 2026Review
- Influence of Uterine Balloon Tamponade Prevalence on Uterine Artery Embolization in the Management of Postpartum Hemorrhage.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the outcomes of uterine artery embolization (UAE) for postpartum hemorrhage in pregnant women with placenta accreta spectrum disorder (PASD) and to assess the risk factors for rebleeding. MATERIALS AND
methodsThis retrospective study evaluated 112 patients with PASD (62 accreta, 40 increta, 10 percreta) who underwent UAE for postpartum hemorrhage between January 2002 and February 2024. The clinical outcomes and rebleeding risk factors were analyzed.
resultsA total of 90 patients (80.4%) were successfully embolized without major complications. Rebleeding occurred in the remaining 22 patients after initial embolization, requiring surgery (n = 11) or repeated embolization (n = 11). The mean time interval between initial UAE and rebleeding was 52.1 h (range, 1-648 h; interquartile range (IQR), 4.0-11.25 h). There were no maternal deaths. Multivariate Cox regression analysis showed that overt disseminated intravascular coagulation (p < 0.001), remnant placenta (p < 0.001), extravasation of contrast media on angiogram (p = 0.005), and the transfused packed red blood cell (p = 0.005) were significant independent factors associated with clinical failure of the embolization.
conclusionUAE represents an effective initial treatment option with a high success rate for postpartum hemorrhage in patients with PASD, especially for those aiming to preserve fertility. However, the possibility of rebleeding should be considered in high-risk patients, and achieving complete hemostasis using permanent embolic agents can be beneficial in such cases. KEY POINTS: Question Does uterine artery embolization effectively manage postpartum hemorrhage in patients with placenta accreta spectrum disorder (PASD), minimizing rebleeding and associated complications? Findings Uterine artery embolization effectively controlled postpartum hemorrhage in PASD. Rebleeding was associated with disseminated intravascular coagulation, remnant placenta, transfused red blood cells, and contrast extravasation. Clinical relevance Uterine artery embolization is a reliable and minimally invasive method for managing postpartum hemorrhage in PASD, with a low complication rate and the potential to preserve fertility. Identifying risk factors can enhance patient outcomes and personalized treatment strategies.
Indexed as
Identifiers
40512219What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.